News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|March 28, 2025

Balancing Approved Therapies and Patient Preference in Parkinson Disease

Author(s)Daniel E. Kremens, MD, JD

An expert discusses the importance of collaborating with patients, emphasizing the value of leading with data when educating them on the efficacy of treatments, and highlights the role of providers in supporting patients as they discover the medications and supplements that work best for them, while advocating for and protecting patients to ensure they can seek the best quality of life.

Episodes in this series

EP. 1 Parkinson Disease: Prevalence and Impact of OFF Episodes and Dyskinesia

EP. 1 Parkinson Disease: Prevalence and Impact of OFF Episodes and Dyskinesia

EP. 2 Recent Medical Advancements: Opportunities and Considerations

EP. 2 Recent Medical Advancements: Opportunities and Considerations

EP. 3 Exciting Pipeline Therapeutics for Parkinson Disease

EP. 3 Exciting Pipeline Therapeutics for Parkinson Disease

EP. 4 Selecting the Best Treatment Options for Patients With Parkinson Disease

EP. 4 Selecting the Best Treatment Options for Patients With Parkinson Disease

EP. 5 Providing a Holistic Approach to Parkinson Disease Care

EP. 5 Providing a Holistic Approach to Parkinson Disease Care

EP. 6 Balancing Approved Therapies and Patient Preference in Parkinson Disease

EP. 6 Balancing Approved Therapies and Patient Preference in Parkinson Disease

EP. 7 Looking Ahead: Future Landscape for Treating OFF Time and Dyskinesia

EP. 7 Looking Ahead: Future Landscape for Treating OFF Time and Dyskinesia

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Evolution of CIDP Clinical Trials and Patient Protection

ByAmit Sachdev, MD, MS

November 13th 2025

FDA Clears Phase 2a Clinical Trial to Test JOTROL in Patients With Parkinson Disease

ByLouie Pasculli

November 11th 2025

Mechanistic Rationale for Factor XIa Inhibition

ByMike Sharma, MD

November 10th 2025

Ensuring a Comprehensive Diagnosis of CIDP and the Role of EMG

ByAmit Sachdev, MD, MS

November 6th 2025

4 experts in this video

Clinical Pearls in Myasthenia Gravis Care

ByJames F. Howard Jr, MD, FAAN,Beth Stein, MD,Andrew Gordon, MD, Ratna Kiran Bhavaraju-Sanka, MD

November 6th 2025

Latest CME

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

In-Person + Virtual Event

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

November 21, 2025

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

John F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhD

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

James F. Howard Jr, MD

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Therapeutic Potential and Early Promise Behind Stem Cell Therapy UX-DA001 in Parkinson Disease

Fenebrutinib Hits Key Phase 3 Marks in Relapsing and Primary Progressive MS

Uniting Organizations to Collectively Advocate for Neuromuscular Diseases: Paul Melmeyer, MPP

BridgeBio Pursues FDA Submission for BBP-418 in LGMD2i/R9 After Positive Topline Phase 3 Results

Evolution of CIDP Clinical Trials and Patient Protection

© 2025 MJH Life Sciences^®

All rights reserved.